Omalizumab in asthmatics with IgE levels > 700 IU/ml

D. Maselli, J. Diaz, J. Peters (San Antonio, United States Of America)

Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Session: Allergen immunotherapy and anti-immunoglobulin E
Session type: Poster Discussion
Number: 266
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Maselli, J. Diaz, J. Peters (San Antonio, United States Of America). Omalizumab in asthmatics with IgE levels > 700 IU/ml. Eur Respir J 2011; 38: Suppl. 55, 266

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Total IgE and Der p 1 (D1) specific IgE in induced sputum (IS) in patients with allergic and non-allergic asthma
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018


Effect of montelukast administration on serum IL-5 and total IgE levels in asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 579s
Year: 2004

IgE levels in asthmatics and non-asthmatics are affected by different SNPs in FCER1A
Source: Annual Congress 2012 - Asthma and the genes: from GWAS to next generation transcriptome analyses
Year: 2012

Total serum IgE in children with unmeasurable concentration of specific IgE (<0.35 kiu/l)
Source: Eur Respir J 2005; 26: Suppl. 49, 400s
Year: 2005

Monitoring free serum IgE in asthma patients treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010

Mycoplasma pneumoniae infection affects total eosinophil count, the serum level of ECP, and interleukin-5 in atopic children
Source: Annual Congress 2012 - Airway infections in children: from risk factors to treatment
Year: 2012

Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001

Serum tryptase in relation to airway hyperresponsiveness – A population study
Source: Annual Congress 2010 - Methods in respiratory epidemiology
Year: 2010

PDCD1 PD-1.3 polymorphism is associated with total IgE and IL-4 levels in Russian patients with atopic asthma
Source: Annual Congress 2009 - Inflammation and airways
Year: 2009

One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 432s
Year: 2002

Increased levels of angiopoietin 1 & 2 in sputum supernatant in smoking asthma
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012


SUPPLEMENT: Omalizumab lowers eNO in children with asthma
Source: ISSN=ISSN 1810-6841, ISBN=, page=S3
Year: 2005

LATE-BREAKING ABSTRACT: Correlation of serum free light chain immunoglobulins with total IgE and food- and respiratory allergen-specific IgE in serum of allergic subjects
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Plasma and urinary concentrations of inhaled salmeterol in healthy and persons with asthma – Quantifying a doping limit
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Changes of total IgE and specific IgE antibody to dermatophagoides pteronyssinus (Dp) in cured asthmatic children
Source: Eur Respir J 2002; 20: Suppl. 38, 334s
Year: 2002

Monitoring free serum IgE in severe asthma patients treated with omalizumab
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011


Cloned Th cells confer airway obstruction upon antigen challenge in the absence of IgE antibody – a model for nonatopic bronchoconstriction
Source: Annual Congress 2009 - Animal models of airways inflammation
Year: 2009


Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011


Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Possible impact of serum IgE variability on dose calculation of omalizumab (anti-IgE)
Source: Eur Respir J 2004; 24: Suppl. 48, 220s
Year: 2004